Covishield and Covaxin mix and match safe: ICMR


Posted on 09 August 2021


For Illustration Purpose Only.


The Indian Council of Medical Study (ICMR) claimed on Sunday that immunising with a first dose of Covishield followed by a second dosage of Covaxin is not only safe but also produces superior immunogenicity, citing preclinical research. The research could pave the path for increased freedom in mixing and matching covid-19 vaccines in India after it has been peer evaluated and recognised. On the 16th of January, India began immunising against covid-19 with the two vaccinations. Covishield is the in-country version of the Oxford-AstraZeneca vaccine manufactured by Serum Institute of India, whereas Covaxin is an inactivated whole virus vaccine (BBV152) developed jointly by the ICMR-National Institute of Virology (ICMR-NIV) and Bharat Biotech International Ltd. The time between the two doses of Covishield was gradually expanded to six to eight weeks, and then to 12 weeks, as more evidence became available. In Uttar Pradesh, a group of people received Covishield as the first dosage, followed by the unintended delivery of Covaxin as the second dose at a six-week interval. “The immunogenicity profile against Alpha, Beta, and Delta variants in the heterologous group was superior. The IgG antibody and neutralizing antibody response of the participants was also significantly higher compared to that in the homologous groups," ICMR stated.


Key Points


  • The Indian Council of Medical Study (ICMR) claimed on Sunday that immunising with a first dose of Covishield followed by a second dosage of Covaxin is not only safe but also produces superior immunogenicity, citing preclinical research.

  • The research could pave the path for increased freedom in mixing and matching covid-19 vaccines in India.



Follow Us On Google Newsstand: Click Here